None listed
Conditions
Brief summary
Peripheral intravenous catheters (PIVCs) are small hollow tubes inserted into veins for medical therapy in most children admitted to a Paediatric Intensive Care Unit (PICU). However, extravasation or ‘leaking’ of fluid into surrounding tissues remains a harmful complication. Nursing surveillance and assessment of PIVCs assists in detection of extravasation. However, demanding clinician workloads and the inability of some patients to communicate symptoms during critical illness has proved early detection challenging. In order to improve early detection of extravasation injuries, ivWatch® was developed as continuous and non-invasive monitor of PIVCs. It consists of a patient monitor, an optical sensor cable, and a sterile, disposable receptacle for attaching the sensor to the patient’s skin, near the PIVC site. Using infrared light, ivWatch® manufacturers claim the device can detect early signs of extravasation. However, there are few clinical data regarding the effectiveness, acceptability and value of ivWatch®. We are undertaking an efficacy trial to test the feasibility of a larger trial to evaluate the effectiveness of ivWatch®, versus surveillance by clinicians, to identify extravasations within the PICU. We believe this technology has the potential to significantly improve treatment provision and increase patient safety within all critical care settings.
Interventions
Brief name: ivWatch® One hundred patients admitted to a Paediatric Intensive Care Unit (PICU) with a peripheral intravenous access device (PIVC) receiving intermediate to high risk infusates and randomised to the ivWatch intervention arm will be provided with the ivWatch® device. The ivWatch® device consists of a sensor ~2 cm in diameter that is attached to the patient’s skin with an adhesive receptacle as close as possible to the centre of the PIVC site (approximately 1 cm), and covered with gauze. The sensor connects to the ivWatch® monitor via a cable. The ivWatch® device will be applied by member of the research team (a Clinical Research Nurse), and monitored hourly by the patient’s bedside nurse throughout the course of their PICU admission or until their PIVC is removed. The patient’s bedside nurse will also continue to monitor the PIVC site hourly for signs of extravasation (per usual, routine clinical practice) in addition to monitoring the ivWatch® patient monitor. All other aspects of PIVC insertion, management and removal will be standardised in accordance with QCH clinical practice guidelines. Insertion, maintenance and removal will be performed by the usual PICU interdisciplinary staff. The ivWatch® device consists of: 1. A patient monitor, 2. An optical sensor cable, and, 3. A sterile, disposable receptacle for attaching the sensor to the patient’s skin, near the PIVC site The ivWatch® uses near infra-red light to continuously monitor the fluid pathway and surrounding tissue for early signs of extravasation. When fluid accumulates in the subcutaneous tissues, there is a significant change in the light scattering, which is recognised by ivWatch® sensor and results in a “YELLOW CHECK IV” notification on the patient monitor, indicating the possibility of extravasation. If the infusion continues and the light signal further drops below the threshold, the patient monitor will return a “RED CHECK IV” notification, indicating probable extravasation. According to the ivWatch® manufacturers, the algorithm used to process the light signal from the sensor is designed to maximize sensitivity and specificity for infiltration events, while minimizing the number of false alarms from other events (e.g., patient movement).
Sponsors
Study design
Eligibility
Inclusion criteria
PIVC anticipated to be in situ for > 24 hours; Patient anticipated to be admitted to PICU for >24 hours; and, Planned administration of one or more intermediate to high risk infusates (as defined by Clark et al. (2013)), via the study PIVC. This includes intermediate [e.g., phenytoin, vancomycin, midazolam, morphine] and high-risk drugs [e.g., vasopressors, calcium, acyclovir, mannitol]).
Exclusion criteria
Previous participation in the ivWatch® study (i.e., previously enrolled in this study and randomized to one of the treatment conditions)